Literature DB >> 7447412

Phlebitis induced by parenteral treatment with flucloxacillin and cloxacillin: a double-blind study.

A Svedhem, K Alestig, M Jertborn.   

Abstract

Two studies were performed on a total of 54 patients with staphylococcal infections. Study I compares with phlebitogenic properties of flucloxacillin after intravenous infusions when either saline or sterile water was used as a solvent. No difference was observed between the two solvents, and the frequency of phlebitis for the total material without respect to solvents was 5% after 1 day of treatment and 13% after 2 days. Study II was a double-blind comparison of phlebitis caused by intravenous infusions of either flucloxacillin or cloxacillin. The frequencies of phlebitis were found to be 18 and 13%, respectively. After 2 days of treatment the frequency of phlebitis increased dramatically for both drugs. All infusions were given through a plastic cannula of 5-cm length and 1.2-mm diameter.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7447412      PMCID: PMC283994          DOI: 10.1128/AAC.18.2.349

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  4 in total

1.  [Endothelial damage caused by the semisynthetic penicillins cloxacillin dicloxacillin and flucloxacillin].

Authors:  D Sinapius; K H Bründel
Journal:  Vasa       Date:  1975       Impact factor: 1.961

2.  [Endothelial lesions due to intravasal injections of drugs].

Authors:  R Gottlob
Journal:  Arzneimittelforschung       Date:  1972-11

3.  [Gangrene following erroneous intra-arterial injection of dicloxacillin].

Authors:  H Ehringer; M Fischer; J H Holzner; H Imhof; K Kubiena; K Lechner; H Pichler; H Schnack; K Seidl; M Staudacher
Journal:  Dtsch Med Wochenschr       Date:  1971-06-25       Impact factor: 0.628

4.  Preventing infection in intravenous therapy.

Authors:  D G Maki
Journal:  Anesth Analg       Date:  1977 Jan-Feb       Impact factor: 5.108

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.